James O. McNamara, M.D.
James O. McNamara, M.D., (Chairman) has been a faculty member for over 30 years in the Duke University School of Medicine where he holds the positions of Duke School of Medicine Professor of Neuroscience and Director of the Center for Translational Neuroscience. Dr. McNamara is a highly regarded leader in the fields of neurology and neurobiology and is one of the scientific founders of NeurOp. His research focuses on the process by which a normal brain becomes epileptic. Dr. McNamara is a past president of the American Epilepsy Society, and he is the recipient of numerous honors and awards. He was elected to the Institute of Medicine in 2005, a component of the National Academy of Sciences, and has received two Javits Neuroscience Investigator Awards from the NIH, as well as a Freedom to Discover Award from Bristol-Myers Squibb. He serves on the editorial boards of Molecular Pharmacology and Neuron. He is also a contributor to Goodman & Gilman’s Pharmacological Basis of Therapeutics and Neuroscience, the leading textbook in the field. He is the author of some 300 publications and abstracts. Dr. McNamara received his M.D. degree from the University of Michigan, Ann Arbor.
Raymond J. Dingledine, Ph.D.
Raymond J. Dingledine, Ph.D., is Professor and Chair of the Department of Pharmacology at Emory University School of Medicine and one of NeurOp’s founders. Prior to joining Emory in 1992, Dr. Dingledine was a professor in the Department of Pharmacology at the University of North Carolina, Chapel Hill. He is widely recognized as one of the foremost experts in the field of neuropharmacology, and his current research primarily focuses on the role of inflammation in disease indications involving seizures. He has published more than 200 research papers during his career and served as editor of Molecular Pharmacology. Dr. Dingledine was elected to the Institute of Medicine in 2010 and is the recipient of numerous other scientific honors and awards, including a Javits Neuroscience Investigator Award from the NIH, the Epilepsy Research Award from the American Epilepsy Society, two Bristol-Myers Squibb Neuroscience Awards, and the PhRMA Career Excellence Award. He is past treasurer of the Society for Neuroscience (SfN) and served on the scientific council of NINDS. He currently chairs the SfN Investment Committee and the Epilepsy Benchmarks Committee, a group charged with helping to set the national research agenda in epilepsy. Dr. Dingledine received his Ph.D. degree in pharmacology from Stanford University.
George (Barney) Koszalka, Ph.D.
George (Barney) Koszalka, Ph.D., joined NeurOp in 2010 as President and CEO to lead the company in a new growth phase to advance its novel and proprietary small molecules. Dr. Koszalka is a senior executive with more than 35 years of leadership experience in global pharmaceutical drug development at Burroughs Wellcome, Glaxo Wellcome, GlaxoSmithKline, Trimeris, Inc., and Argolyn Biosciences. He has extensive knowledge of pharmaceutical R&D, joint ventures, business development, product development and medical marketing. Dr. Koszalka has initiated and advanced numerous preclinical and clinical projects and has contributed in a significant manner to the discovery, development and/or lifecycle management of 12 marketed drugs. He serves as an editor for Current Opinion in Investigational Drugs and chairs the scientific advisory board for the Consortium for Parasitic Drug Development, funded by the Bill & Melinda Gates Foundation. He received his Ph.D. in biochemistry from North Carolina State University.
Dennis C. Liotta, Ph.D.
Dennis Liotta, Ph.D., has helped to transform HIV/AIDS from a death sentence to a chronic infection in which patients are able to live active, near normal lives. The Emory University Office of Technology Transfer estimates that greater than 90 percent of all of the HIV-infected persons in the U.S. take (or have taken) one of the drugs he invented. Over the past two and a half decades, Dr. Liotta’s research has focused on the discovery and development of novel antiviral, anticancer and anti-inflammatory therapeutic agents. He is one of the leaders of the Emory team that discovered the antiviral drug, Emtriva® (emtricitabine), which was approved for treating HIV in July 2003. Emtriva is a component of the ground breaking, once-a-day, triple-combination therapy, Atripla®, which is now universally accepted as the drug combination of choice for treating HIV-infected patients. In addition, he is the inventor of record for several clinically important antivirals, including lamivudine, Reverset®, Racivir® and elvucitabine. He is also the lead inventor of Q-122, a safe, orally available clinical agent for controlling hot flashes in post-menopausal women. Dr. Liotta received his Ph.D. from CUNY and is a Samuel Candler Dobbs Professor of Chemistry at Emory University where he has been for 40 years. He has received numerous awards during his tenure including Distinguished Faculty Lecturer and the Emory Williams Award. He has been inducted into the National Academy of Inventors for his contributions to drug discovery and development, as well as to the ACS (American Chemical Society) Medicinal Chemistry Hall of Fame.
Robert R. Bonczek, J.D.
Robert R. Bonczek is president, CFO, and general counsel at b3bio, Inc., a biotechnology company, and founding partner and president of AspenTree Capital, a boutique investment company. His past experience includes being CFO and general counsel at Trimeris, Inc., where he helped the biotechnology company through an IPO, secondary equity offerings, additional private placements, and a major collaboration agreement with Roche, as well as other collaborations. He has also served as a full-time legal consultant to Wilmer Hale and worked with Donaldson, Lufkin & Jenrette in their merchant banking area. Prior to that, Mr. Bonczek held various executive-level roles, including chief counsel and worldwide director of safety, health and environmental affairs at DuPont/Conoco. Mr. Bonczek serves on a number of boards including b3 bio, AspenTree Capital, ELS Services, and K2 Pure; he is also on the advisory boards of Caxton Advantage Healthcare Fund and Centre Partners. He earned degrees in chemistry and law from the University of North Carolina at Chapel Hill and an MBA from the Wharton School at the University of Pennsylvania.